EUVIMEDEUVIMED entdecken
Open Access

Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors

Sixten Harborg, Deirdre Cronin-Fenton, Maj-Britt Raaby Jensen, Thomas P Ahern, Marianne Ewertz, Signe Borgquist

JAMA Network Open · 13.10.2023 · 6 (10) · e2337780

DOI: 10.1001/jamanetworkopen.2023.37780 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 13.10.2023. Verfasst von Sixten Harborg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Aarhus University Hospital/Aarhus University, Aarhus, Denmark. Hauptthemen laut MEDLINE: Breast Neoplasms, Obesity, Morbid. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Clinical studies confirm that obesity is a risk factor for recurrence in postmenopausal women with hormone receptor–positive (HR+) breast cancer. Evidence suggests that women with obesity do not obtain similar protection from aromatase inhibitors as women with healthy weight.

Objective

To examine the associations of body mass index (BMI) with recurrence. Design, Setting, and Participants The cohort study was conducted using data from the Danish Breast Cancer Group and enrolled postmenopausal women diagnosed with stage I to III HR+ breast cancer from 1998 through 2016. Data analysis was conducted from November 2022 to April 2023. Exposures BMI was classified as (1) healthy weight (18.5-24.9), (2) overweight (25.0-29.9), (3) obesity (30.0-34.9), and (4) severe obesity (≥35.0) using the World Health Organization guidelines. Healthy weight was considered the reference group in statistical analyses. Main Outcomes and Measures Follow-up began 6 months after breast cancer surgery and continued until the first event of recurrence, contralateral breast cancer, new primary malignant neoplasm, death, emigration, end of clinical follow-up at 10 years, or September 25, 2018. Cox regression was used to estimate crude and adjusted hazard ratios with 95% CIs, adjusting for patient, tumor, and treatment characteristics.

Results

A total of 13 230 patients (median [IQR] age at diagnosis, 64.4 [58.6-70.2] years) with information on BMI were enrolled. There were 1587 recurrences with a median (IQR) potential estimated follow-up of 6.2 (3.6-8.5) years. Multivariable analyses revealed increased recurrence hazards associated with obesity (adjusted hazard ratio, 1.18 [95% CI, 1.01-1.37]) and severe obesity (adjusted hazard ratio, 1.32 [95% CI, 1.08-1.62]) vs patients with healthy weight. Patients with overweight had a greater risk, but the results were not statistically significant (adjusted hazard ratio, 1.10 [95% CI, 0.97-1.24]). Conclusions and Relevance In this study, obesity was associated with an increased risk of breast cancer recurrence among postmenopausal patients with HR+ early-stage breast cancer treated with aromatase inhibitors. Physicians should be aware of the significance of obesity on breast cancer outcomes to secure optimal treatment benefit in all patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsObesity, MorbidHumansFemaleMiddle AgedAgedAromatase InhibitorsOverweightCohort StudiesNeoplasm Recurrence, LocalObesity

Substanzen

Aromatase Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, Aarhus University Hospital/Aarhus University, Aarhus, Denmark.
  • Department of Clinical Epidemiology, Aarhus University, Aarhus N, Denmark.
  • Danish Breast Cancer Group, Copenhagen University Hospital, Copenhagen, Denmark.
  • Department of Surgery, Larner College of Medicine, University of Vermont, Burlington, Vermont.
  • Oncology Research Unit, Department of Clinical Research, University of Southern Denmark, Odense C, Denmark.
  • Department of Clinical Sciences, Lund, Oncology, Lund University, Sweden.

Zitieren

APA

Harborg, S., Cronin-Fenton, D., Jensen, M. R., Ahern, T. P., Ewertz, M., & Borgquist, S. (2023). Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors. JAMA Network Open, 6(10), e2337780. https://doi.org/10.1001/jamanetworkopen.2023.37780

Vancouver

Harborg S, Cronin-Fenton D, Jensen MR, Ahern TP, Ewertz M, Borgquist S. Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors. JAMA Network Open. 2023;6(10):e2337780. doi:10.1001/jamanetworkopen.2023.37780

BibTeX
@article{Harborg2023,
  author = {Harborg, Sixten and Cronin-Fenton, Deirdre and Jensen, Maj-Britt Raaby and Ahern, Thomas P and Ewertz, Marianne and Borgquist, Signe},
  title = {Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {10},
  pages = {e2337780},
  doi = {10.1001/jamanetworkopen.2023.37780}
}
Kostenlos starten →